Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week, multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension with eplivanserin for a 40-week period.

Trial Profile

Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week, multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension with eplivanserin for a 40-week period.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Eplivanserin (Primary)
  • Indications Sleep maintenance insomnia
  • Focus Registrational; Therapeutic Use
  • Acronyms EPLILONG
  • Sponsors Sanofi
  • Most Recent Events

    • 25 Mar 2009 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Planned number of patients changed from 1120 to 1155 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top